EGFR and breast carcinoma: Given that the majority (83%) of triple negative tumors in the AMBER consortium was classified as basal-like using PAM50, we proceeded with the 1% threshold for EGFR or CK5/6 expression in order to maximize sensitivity and overall accuracy for PAM50-based basal-like breast cancer, and to limit the number of tumors misclassified as triple negative non-basal-like.